Revance Therapeutics And Teoxane Entered Into The Sixth Amendment To The Exclusive Distribution Agreement - 8K Filing
Revance Therapeutics And Teoxane Entered Into The Sixth Amendment To The Exclusive Distribution Agreement - 8K Filing
As previously disclosed on a Current Report on Form 8-K filed on January 10, 2020, the Company entered into the Exclusive Distribution Agreement with Teoxane on January 10, 2020, pursuant to which Teoxane granted the Company with the exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers and future Hyaluronic Acid filler advancements by Teoxane in the United States, its territories and possessions (collectively, the "RHA Collection"), which is manufactured in Switzerland by Teoxane.
根據2020年1月10日提交的8-k表格,公司與Teoxane簽訂了獨家分銷協議,根據協議,Teoxane授予公司在美國及其領土和地區獨家進口、推廣、銷售和分發Teoxane的彈性透明質酸皮膚填充劑系列以及Teoxane未來的透明質酸填充劑創新產品的權利(統稱爲「RHA系列」),這些產品在瑞士由Teoxane製造。
The Sixth Amendment, among other things, includes (i) revised brand guidelines and the adoption of a marketing task force to review current and planned product promotional materials, (ii) revised medical training materials and the adoption of a medical education task force to promote the exchange of best practices with respect to medical education, (iii) an update to the buffer stock methodology that is aligned with new purchase commitments and (iv) agreed on minimum purchase commitments through 2029.
第六次修正案包括(i)修訂的品牌指南和成立市場任務組,審查當前和計劃中的產品推廣材料,(ii)修訂的醫學培訓材料和成立醫學教育任務組,促進醫學教育的最佳實踐交流,(iii)與新的採購承諾一致的庫存緩衝方法更新以及(iv)2029年前達成的最低採購承諾。
譯文內容由第三人軟體翻譯。